

Supplement notes

PIs from the PRACTICAL (<http://practical.icr.ac.uk/>), CRUK, BPC3, CAPS, PEGASUS consortia:

Rosalind A. Eeles^{1,2}, Christopher A. Haiman³, Zsofia Kote-Jarai¹, Fredrick R. Schumacher^{4,5}, Sara Benlloch^{6,1}, Ali Amin Al Olama^{6,7}, Kenneth R. Muir⁸, Sonja I. Berndt⁹, David V. Conti³, Fredrik Wiklund¹⁰, Stephen Chanock⁹, Ying Wang¹¹, Catherine M. Tangen¹², Jyotsna Batra^{13,14}, Judith A. Clements^{13,14}, APCB BioResource (Australian Prostate Cancer BioResource)^{15,14}, Henrik Grönberg¹⁰, Nora Pashayan^{16,17}, Johanna Schleutker^{18,19}, Demetrius Albanes⁹, Stephanie Weinstein⁹, Alicja Wolk²⁰, Catharine M. L. West²¹, Lorelei A. Mucci²², Géraldine Cancel-Tassin^{23,24}, Stella Koutros⁹, Karina Dalsgaard Sørensen^{25,26}, Eli Marie Grindedal²⁷, David E. Neal^{28,29,30}, Freddie C. Hamdy^{31,32}, Jenny L. Donovan³³, Ruth C. Travis³⁴, Robert J. Hamilton^{35,36}, Sue Ann Ingles³⁷, Barry S. Rosenstein³⁸, Yong-Jie Lu³⁹, Graham G. Giles^{40,41,42}, Robert J. MacInnis^{40,41}, Adam S. Kibel⁴³, Ana Vega^{44,45,46}, Manolis Kogevinas^{47,48,49,50}, Kathryn L. Penney⁵¹, Jong Y. Park⁵², Janet L. Stanford^{53,54}, Cezary Cybulski⁵⁵, Børge G. Nordestgaard^{56,57}, Sune F. Nielsen^{56,57}, Hermann Brenner^{58,59,60}, Christiane Maier⁶¹, Jeri Kim⁶², Esther M. John⁶³, Manuel R. Teixeira^{64,65,66}, Susan L. Neuhausen⁶⁷, Kim De Ruyck⁶⁸, Azad Razack⁶⁹, Lisa F. Newcomb^{53,70}, Davor Lessel⁷¹, Radka Kaneva⁷², Nawaid Usmani^{73,74}, Frank Claessens⁷⁵, Paul A. Townsend^{76,77}, Jose Esteban Castela⁷⁸, Monique J. Roobol⁷⁹, Florence Menegaux⁸⁰, Kay-Tee Khaw⁸¹, Lisa Cannon-Albright^{82,83}, Hardev Pandha⁷⁷, Stephen N. Thibodeau⁸⁴, David J. Hunter⁸⁵, Peter Kraft⁸⁶, William J. Blot^{87,88}, Elio Riboli⁸⁹

¹The Institute of Cancer Research, London, SM2 5NG, UK

²Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK

³Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90015, USA

⁴Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH 44106-7219, USA

⁵Seidman Cancer Center, University Hospitals, Cleveland, OH 44106, USA.

⁶Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK

⁷University of Cambridge, Department of Clinical Neurosciences, Stroke Research

Group, R3, Box 83, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK

⁸Division of Population Health, Health Services Research and Primary Care, University of Manchester, Oxford Road, Manchester, M13 9PL, UK

⁹Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, 20892, USA

¹⁰Department of Medical Epidemiology and Biostatistics, Karolinska Institute, SE-171 77 Stockholm, Sweden

¹¹Department of Population Science, American Cancer Society, 250 Williams Street, Atlanta, GA 30303, USA

¹²SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

¹³Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane QLD 4059, Australia

¹⁴Translational Research Institute, Brisbane, Queensland 4102, Australia

¹⁵Australian Prostate Cancer Research Centre-Qld, Queensland University of Technology, Brisbane; Prostate Cancer Research Program, Monash University, Melbourne; Dame Roma Mitchell Cancer Centre, University of Adelaide, Adelaide; Chris O'Brien Lifehouse and

¹⁶Department of Applied Health Research, University College London, London, WC1E 7HB, UK

¹⁷Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Laboratory, Worts Causeway, Cambridge, CB1 8RN, UK

¹⁸Institute of Biomedicine, University of Turku, Finland

¹⁹Department of Medical Genetics, Genomics, Laboratory Division, Turku University Hospital, PO Box 52, 20521 Turku, Finland

²⁰Department of Surgical Sciences, Uppsala University, 75185 Uppsala, Sweden

²¹Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Radiotherapy Related Research, The Christie Hospital NHS Foundation Trust, Manchester, M13 9PL UK

²²Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA

²³CeRePP, Tenon Hospital, F-75020 Paris, France.

²⁴Sorbonne Universite, GRC n°5 , AP-HP, Tenon Hospital, 4 rue de la Chine, F-75020 Paris, France

²⁵Department of Molecular Medicine, Aarhus University Hospital, Palle Juul-Jensen Boulevard 99, 8200 Aarhus N, Denmark

²⁶Department of Clinical Medicine, Aarhus University, DK-8200 Aarhus N

²⁷Department of Medical Genetics, Oslo University Hospital, 0424 Oslo, Norway

²⁸Nuffield Department of Surgical Sciences, University of Oxford, Room 6603, Level 6, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK

²⁹University of Cambridge, Department of Oncology, Box 279, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK

³⁰Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre,

Cambridge, CB2 0RE, UK

³¹Nuffield Department of Surgical Sciences, University of Oxford, Oxford, OX1 2JD, UK

³²Faculty of Medical Science, University of Oxford, John Radcliffe Hospital, Oxford, UK

³³Population Health Sciences, Bristol Medical School, University of Bristol, BS8 2PS, UK

³⁴Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK

³⁵Dept. of Surgical Oncology, Princess Margaret Cancer Centre, Toronto ON M5G 2M9, Canada

³⁶Dept. of Surgery (Urology), University of Toronto, Canada

³⁷Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90015, USA

³⁸Department of Radiation Oncology and Department of Genetics and Genomic Sciences, Box 1236, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA

³⁹Centre for Cancer Biomarker and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M 6BQ, UK

⁴⁰Cancer Epidemiology Division, Cancer Council Victoria, 615 St Kilda Road, Melbourne, VIC 3004, Australia

⁴¹Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Grattan Street, Parkville, VIC 3010, Australia

⁴²Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria 3168, Australia

⁴³Division of Urologic Surgery, Brigham and Womens Hospital, 75 Francis Street, Boston, MA 02115, USA

⁴⁴Fundación Pública Galega Medicina Xenómica, Santiago de Compostela, 15706, Spain.

⁴⁵Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De Compostela, 15706, Spain.

⁴⁶Centro de Investigación en Red de Enfermedades Raras (CIBERER), Spain

⁴⁷ISGlobal, Barcelona, Spain

⁴⁸IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

⁴⁹Universitat Pompeu Fabra (UPF), Barcelona, Spain

⁵⁰CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain

⁵¹Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA 02115, USA

⁵²Department of Cancer Epidemiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA

⁵³Division of Public Health Sciences, Fred Hutchinson Cancer Research Center,

Seattle, Washington, 98109-1024, USA

⁵⁴Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington 98195, USA

⁵⁵International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, 70-115 Szczecin, Poland

⁵⁶Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark

⁵⁷Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, 2200 Copenhagen, Denmark

⁵⁸Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), D-69120, Heidelberg, Germany

⁵⁹German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany

⁶⁰Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany

⁶¹Humangenetik Tuebingen, Paul-Ehrlich-Str 23, D-72076 Tuebingen, Germany

⁶²The University of Texas M. D. Anderson Cancer Center, Department of Genitourinary Medical Oncology, 1515 Holcombe Blvd., Houston, TX 77030, USA

⁶³Departments of Epidemiology & Population Health and of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94304 USA

⁶⁴Department of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), 4200-072 Porto, Portugal

⁶⁵Biomedical Sciences Institute (ICBAS), University of Porto, 4050-313 Porto, Portugal

⁶⁶Cancer Genetics Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), 4200-072 Porto, Portugal

⁶⁷Department of Population Sciences, Beckman Research Institute of the City of Hope, 1500 East Duarte Road, Duarte, CA 91010, 626-256-HOPE (4673)

⁶⁸Ghent University, Faculty of Medicine and Health Sciences, Basic Medical Sciences, Proeftuinstraat 86, B-9000 Gent

⁶⁹Department of Surgery, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

⁷⁰Department of Urology, University of Washington, 1959 NE Pacific Street, Box 356510, Seattle, WA 98195, USA

⁷¹Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, D-20246 Hamburg, Germany

⁷²Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria

⁷³Department of Oncology, Cross Cancer Institute, University of Alberta, 11560 University Avenue, Edmonton, Alberta, Canada T6G 1Z2

⁷⁴Division of Radiation Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada T6G 1Z2

- ⁷⁵Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, BE-3000, Belgium
- ⁷⁶Division of Cancer Sciences, Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Health Innovation Manchester, University of Manchester, M13 9WL
- ⁷⁷The University of Surrey, Guildford, Surrey, GU2 7XH, UK
- ⁷⁸Genetic Oncology Unit, CHUVI Hospital, Complejo Hospitalario Universitario de Vigo, Instituto de Investigación Biomédica Galicia Sur (IISGS), 36204, Vigo (Pontevedra), Spain
- ⁷⁹Department of Urology, Erasmus University Medical Center, 3015 CE Rotterdam, The Netherlands
- ⁸⁰"Exposome and Heredity", CESP (UMR 1018), Faculté de Médecine, Université Paris-Saclay, Inserm, Gustave Roussy, Villejuif
- ⁸¹Clinical Gerontology Unit, University of Cambridge, Cambridge, CB2 2QQ, UK
- ⁸²Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah 84132, USA
- ⁸³George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah 84148, USA
- ⁸⁴Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
- ⁸⁵Nuffield Department of Population Health, University of Oxford, United Kingdom
- ⁸⁶Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
- ⁸⁷Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 800, Nashville, TN 37232 USA.
- ⁸⁸International Epidemiology Institute, Rockville, MD 20850, USA
- ⁸⁹Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, SW7 2AZ, UK

CRUK and PRACTICAL consortium

This work was supported by the Canadian Institutes of Health Research, European Commission's Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now PCUK), The Orchid Cancer Appeal, Rosetrees Trust, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, and Manchester NIHR Biomedical Research Centre. The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall's. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I]. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Research reported in this publication also received support from the National Cancer Institute of the National Institutes of Health under Award Numbers U10 CA37429 (CD Blanke), and UM1 CA182883 (CM Tangen/IM Thompson). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A111174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

BPC3

The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 to

E.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).

CAPS

CAPS GWAS study was supported by the Cancer Risk Prediction Center (CRiSP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, (grant no K2010-70X-20430-04-3), the Swedish Cancer Foundation (grant no 09-0677), the Hedlund Foundation, the Soederberg Foundation, the Enqvist Foundation, ALF funds from the Stockholm County Council. Stiftelsen Johanna Hagstrand och Sigfrid Linner's Minne, Karlsson's Fund for urological and surgical research.

PEGASUS

PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.